Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2021

Open Access 01-12-2021 | Prostate Cancer | Review

Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance

Authors: Chunyang Wang, Qi Chen, Huachao Xu

Published in: Discover Oncology | Issue 1/2021

Login to get access

Abstract

Globally, prostate cancer ranks second in cancer burden of the men. It occurs more frequently in black men compared to white or Asian men. Usually, high rates exist for men aged 60 and above. In this review, we focus on the Wnt/β-catenin signal transduction pathway in prostate cancer since many studies have reported that β-catenin can function as an oncogene and is important in Wnt signaling. We also relate its expression to the androgen receptor and MMP-7 protein, both critical to prostate cancer pathogenesis. Some mutations in the androgen receptor also impact the androgen-β-catenin axis and hence, lead to the progression of prostate cancer. We have also reviewed MiRNAs that modulate this pathway in prostate cancer. Finally, we have summarized the impact of Wnt/β-catenin pathway proteins in the drug resistance of prostate cancer as it is a challenging facet of therapy development due to the complexity of signaling pathways interaction and cross-talk.
Literature
1.
2.
Sharma RP, Chopra VL. Effect of the wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. Dev Biol. 1976;48(2):461–5.PubMedCrossRef
3.
Nusse R, et al. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature. 1984;307(5947):131–6.PubMedCrossRef
4.
De A. Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin. 2011;43(10):745–56.PubMedCrossRef
5.
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.PubMedCrossRef
6.
7.
van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev. 2003;13(1):28–33.PubMedCrossRef
8.
Grumolato L, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 2010;24(22):2517–30.PubMedPubMedCentralCrossRef
9.
Ho HY, et al. Wnt5a-Ror-dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci USA. 2012;109(11):4044–51.PubMedPubMedCentralCrossRef
10.
Schlesinger A, et al. Wnt pathway components orient a mitotic spindle in the early Caenorhabditis elegans embryo without requiring gene transcription in the responding cell. Genes Dev. 1999;13(15):2028–38.PubMedPubMedCentralCrossRef
11.
Walston T, et al. Multiple Wnt signaling pathways converge to orient the mitotic spindle in early C. elegans embryos. Dev Cell. 2004;7(6):831–41.PubMedCrossRef
12.
Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev. 2009;23(3):265–77.PubMedCrossRef
13.
Qiu W, Chen L, Kassem M. Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochem Biophys Res Commun. 2011;413(1):98–104.PubMedCrossRef
14.
Heinonen KM, et al. Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS ONE. 2011;6(4): e19279.PubMedPubMedCentralCrossRef
15.
Jeays-Ward K, et al. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development. 2003;130(16):3663–70.PubMedCrossRef
16.
Zhao L, et al. E6-induced selective translation of WNT4 and JIP2 promotes the progression of cervical cancer via a noncanonical WNT signaling pathway. Signal Transduct Target Ther. 2019;4:32.PubMedPubMedCentralCrossRef
17.
Hardy KM, et al. Non-canonical Wnt signaling through Wnt5a/b and a novel Wnt11 gene, Wnt11b, regulates cell migration during avian gastrulation. Dev Biol. 2008;320(2):391–401.PubMedPubMedCentralCrossRef
18.
Humphries AC, Mlodzik M. From instruction to output: Wnt/PCP signaling in development and cancer. Curr Opin Cell Biol. 2018;51:110–6.PubMedCrossRef
19.
Li R, et al. WNT6 promotes the migration and differentiation of human dental pulp cells partly through c-Jun N-terminal kinase signaling pathway. J Endod. 2014;40(7):943–8.PubMedCrossRef
20.
Wang, Q., et al., A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One, 2010. 5(5): p. e10456.
21.
Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (review). Int J Mol Med. 2017;40(3):587–606.PubMedPubMedCentral
22.
23.
24.
25.
Bello JO, et al. Regulation of the Wnt/beta-catenin signaling pathway by human papillomavirus E6 and E7 oncoproteins. Viruses. 2015;7(8):4734–55.PubMedCrossRef
26.
Maye P, et al. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J Biol Chem. 2004;279(23):24659–65.PubMedCrossRef
27.
28.
Medrek C, et al. Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J Biol Chem. 2009;284(16):10968–79.PubMedPubMedCentralCrossRef
29.
Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9(8):418–28.PubMedCrossRef
30.
31.
Arend RC, et al. The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772–9.PubMedCrossRef
32.
33.
34.
35.
Yun EJ, et al. Wnt/beta-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis. 2020;11(9):771.PubMedPubMedCentralCrossRef
36.
Yu X, et al. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 2011;30(16):1868–79.PubMedCrossRef
37.
Moparthi L, Pizzolato G, Koch S. Wnt activator FOXB2 drives the neuroendocrine differentiation of prostate cancer. Proc Natl Acad Sci USA. 2019;116(44):22189–95.PubMedPubMedCentralCrossRef
38.
Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res. 1998;58(12):2520–3.PubMed
39.
Chen G, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101(6):1345–56.PubMedCrossRef
40.
de la Taille A, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003;9(5):1801–7.PubMed
41.
Schweizer L, et al. The androgen receptor can signal through Wnt/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 2008;9:4.PubMedPubMedCentralCrossRef
42.
Thiele S, et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem. 2011;112(6):1593–600.PubMedCrossRef
43.
Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int J Oncol. 2001;19(5):1003–7.PubMed
44.
Hall CL, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65(17):7554–60.PubMedCrossRef
45.
Verras M, et al. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 2004;64(24):8860–6.PubMedCrossRef
46.
Ayub SG, Kaul D, Ayub T. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer. Cancer Genet. 2015;208(6):289–302.PubMedCrossRef
47.
Zhao S, et al. MiR-26a inhibits prostate cancer progression by repression of Wnt5a. Tumour Biol. 2014;35(10):9725–33.PubMedCrossRef
48.
Yokoyama NN, et al. Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol. 2014;2(1):27–44.PubMedPubMedCentral
49.
Yamamoto H, et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene. 2010;29(14):2036–46.PubMedCrossRef
50.
Sandsmark E, et al. A novel non-canonical Wnt signature for prostate cancer aggressiveness. Oncotarget. 2017;8(6):9572–86.PubMedCrossRef
51.
52.
Zhu H, et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res. 2004;64(21):7918–26.PubMedCrossRef
53.
Kirikoshi H, Katoh M. Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol. 2002;21(4):895–900.PubMed
54.
Kirikoshi H, Sekihara H, Katoh M. Molecular cloning and characterization of human WNT7B. Int J Oncol. 2001;19(4):779–83.PubMed
55.
Katoh M, et al. Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family. Oncogene. 1996;13(4):873–6.PubMed
56.
Madueke I. The roles of canonical Wnt2 and Wnt10b in prostate gland development and prostate cancer progression. Doctoral dissertation, University of Illinois at Chicago. 2015.
57.
Schneider JA, Logan SK. Revisiting the role of Wnt/beta-catenin signaling in prostate cancer. Mol Cell Endocrinol. 2018;462(Pt A):3–8.PubMedCrossRef
58.
Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019;37(3):288–95.PubMedCrossRef
59.
Chen SY, et al. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol. 2006;26(3):929–39.PubMedPubMedCentralCrossRef
60.
Seo WI, et al. Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP. Biochem Biophys Res Commun. 2017;486(4):1034–9.PubMedCrossRef
61.
62.
Taplin ME, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332(21):1393–8.PubMedCrossRef
63.
Marcelli M, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60(4):944–9.PubMed
64.
Shi XB, et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002;62(5):1496–502.PubMed
65.
Schoenberg MP, et al. Microsatellite mutation (CAG24–>18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun. 1994;198(1):74–80.PubMedCrossRef
66.
Watanabe M, et al. Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn J Clin Oncol. 1997;27(6):389–93.PubMedCrossRef
67.
Steinkamp MP, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009;69(10):4434–42.PubMedPubMedCentralCrossRef
68.
Takahashi H, et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res. 1995;55(8):1621–4.PubMed
69.
Sanchez D, et al. Androgen receptor mutations are associated with Gleason score in localized prostate cancer. BJU Int. 2006;98(6):1320–5.PubMedCrossRef
70.
Yang F, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem. 2002;277(13):11336–44.PubMedCrossRef
71.
Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 2006;237(1):22–32.PubMedCrossRef
72.
Jung SJ, et al. Clinical significance of Wnt/beta-catenin signalling and androgen receptor expression in prostate cancer. World J Mens Health. 2013;31(1):36–46.PubMedPubMedCentralCrossRef
73.
Grindel BJ, et al. Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol. 2014;36:64–76.PubMedPubMedCentralCrossRef
74.
Reid JC, et al. Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases. Am J Cancer Res. 2017;7(11):2257–74.PubMedPubMedCentral
75.
Hashimoto K, et al. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol. 1998;160(5):1872–6.PubMedCrossRef
76.
Zhang Q, et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. 2017;36(5):687–99.PubMedCrossRef
77.
Santiago L, et al. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res. 2017;7(6):1389–406.PubMedPubMedCentral
78.
Gravdal K, et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13(23):7003–11.PubMedCrossRef
79.
Ghali F, et al. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. J Clin Oncol. 2020;38:203.CrossRef
80.
81.
82.
Liu Y, et al. Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/beta-catenin signaling. Oncol Rep. 2017;37(3):1521–8.PubMedCrossRef
83.
Cheng S, et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):661–9.PubMedPubMedCentralCrossRef
84.
85.
86.
Cui Y, et al. miR-15a-3p suppresses prostate cancer cell proliferation and invasion by targeting SLC39A7 Via downregulating Wnt/beta-catenin signaling pathway. Cancer Biother Radiopharm. 2019;34(7):472–9.PubMedCrossRef
87.
Pashaei E, et al. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS ONE. 2017;12(6): e0179543.PubMedPubMedCentralCrossRef
88.
Hsieh IS, et al. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34(3):530–8.PubMedCrossRef
89.
Yu Z, et al. miR138 modulates prostate cancer cell invasion and migration via Wnt/betacatenin pathway. Mol Med Rep. 2018;17(2):3140–5.PubMed
90.
Situ J, et al. MicroRNA-939 directly targets HDGF to inhibit the aggressiveness of prostate cancer via deactivation of the WNT/beta-catenin pathway. Onco Targets Ther. 2020;13:4257–70.PubMedPubMedCentralCrossRef
91.
Guan H, et al. MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/beta-catenin signaling. Oncotarget. 2017;8(9):14693–707.PubMedPubMedCentralCrossRef
92.
Wang D, et al. MiR-182 promotes prostate cancer progression through activating Wnt/beta-catenin signal pathway. Biomed Pharmacother. 2018;99:334–9.PubMedCrossRef
93.
94.
Liang X, et al. MicroRNA-1297 inhibits prostate cancer cell proliferation and invasion by targeting the AEG-1/Wnt signaling pathway. Biochem Biophys Res Commun. 2016;480(2):208–14.PubMedCrossRef
95.
Liu B, et al. miR-1303 promotes the proliferation, migration and invasion of prostate cancer cells through regulating the Wnt/beta-catenin pathway by targeting DKK3. Exp Ther Med. 2019;18(6):4747–57.PubMedPubMedCentral
96.
Dong B, et al. MiR-34a affects G2 arrest in prostate cancer PC3 cells via Wnt pathway and inhibits cell growth and migration. Eur Rev Med Pharmacol Sci. 2020;24(16):8349–58.PubMed
97.
Nadiminty N, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012;287(2):1527–37.PubMedCrossRef
98.
Wan X, et al. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. Int J Biochem Cell Biol. 2016;79:249–60.PubMedCrossRef
99.
Shiina M, et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget. 2017;8(5):8356–68.PubMedCrossRef
100.
Kroiss A, et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 2015;34(22):2846–55.PubMedCrossRef
101.
Larne O, et al. miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis. 2015;36(8):858–66.PubMedCrossRef
102.
103.
104.
Sun T, et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014;33(21):2790–800.PubMedCrossRef
105.
Epis MR, et al. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014;116(1):67–75.PubMedCrossRef
106.
Meng D, et al. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells. Int J Biochem Cell Biol. 2016;73:30–40.PubMedCrossRef
107.
Yeh Y, et al. Wnt/beta-catenin signaling and prostate cancer therapy resistance. Adv Exp Med Biol. 2019;1210:351–78.PubMedCrossRef
108.
109.
Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12–23.PubMedCrossRef
110.
111.
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3(2):64–76.PubMedPubMedCentral
112.
113.
Zhong Z, Virshup DM. Wnt signaling and drug resistance in cancer. Mol Pharmacol. 2020;97(2):72–89.PubMedCrossRef
114.
Zhang Z, et al. Inhibition of the Wnt/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer. Cancer Res. 2018;78(12):3147–62.PubMedPubMedCentralCrossRef
115.
116.
Cristobal I, et al. Cross talk between Wnt/beta-catenin and CIP2A/Plk1 signaling in prostate cancer: promising therapeutic implications. Mol Cell Biol. 2016;36(12):1734–9.PubMedPubMedCentralCrossRef
117.
Chen WS, et al. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(5):562–71.PubMedPubMedCentralCrossRef
118.
Kohli M, et al. Association of Wnt pathway activation with prechemotherapy abiraterone acetate resistance in metastatic castration-resistant prostate cancer (mCRPC) by genome-wide analysis of metastases. J Clin Oncol. 2017;35:175.CrossRef
119.
Vesel M, et al. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res. 2017;18(1):52.PubMedPubMedCentralCrossRef
120.
121.
Zhu M, et al. Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt/beta-catenin pathway. Phytother Res. 2020;34(4):817–24.PubMedCrossRef
122.
Bian P, et al. Activated Wnt/beta-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. Life Sci. 2020;254: 116816.PubMedCrossRef
123.
Cojoc M, et al. Aldehyde dehydrogenase is regulated by beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res. 2015;75(7):1482–94.PubMedCrossRef
Metadata
Title
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance
Authors
Chunyang Wang
Qi Chen
Huachao Xu
Publication date
01-12-2021
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-021-00433-6

Other articles of this Issue 1/2021

Discover Oncology 1/2021 Go to the issue

Research

Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer

Research

FAM65A as a novel prognostic biomarker in human tumors reveal by a pan-cancer analysis

Review

O-GlcNAcylation links oncogenic signals and cancer epigenetics

Research

The prognostic significance of primary tumor size in squamous cell carcinoma of the penis

Research

Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion

Research

Volume-outcome relationship in rectal cancer surgery
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits